toms may be an early sign of allergic and occupational airway disease. There is also the possibility that a more general relation between rhinitis and asthma exists. This idea is not novel and at the turn of the century it led to the introduction of different treatments for asthma. 2 This editorial considers what can be learnt about inflammatory mechanisms by studying the readily accessible human nasal mucosa rather than the relatively inaccessible bronchial mucosa.
Nasal treatments of asthma In the latter half of the previous century "the snare, the knife, or caustics" were frequently used to treat chronic catarrhal affections of the upper air tract.' Moreover, asthma was reported to be cured by these radical measures. Francis Rackemann, however, in 1931, in a review4 on connections between asthma and the nose, concluded that the widespread attempts to cure asthma by surgically removing foci of infection in the nasal and oral passages were distinctly disappointing. On the other hand, Rackemann also noted that "lesions in the nose and the sinuses are so common in asthma as to be almost a clinical characteristic and they may be of diagnostic importance."
Neural mechanisms have been a basis for connecting nasal and bronchial disease. In 1919 Sluder' described asthma "as a nasal reflex." Dixon and Brodie6 had previously shown in dogs that stimulation of the nasal mucosa could produce bronchospasm. One of the treatments that followed was topical cocaine to produce local anaesthesia of the nasal mucosa. (In the 1880s cocaine had already been used as a mucosal decongestant' in both rhinitis and asthma.) Other nasal treatments in vogue 100 years ago might also have produced anaesthesia or, indeed, required this effect to be endured. Capsaicin, the pungent part of Spanish pepper, is but one example7 of a painful local treatment of that time. Capsaicin is now being rediscovered as a nasal drug, but its current praise is based more on interaction with neuropeptides than on clinical efficacy. Nasal anaesthesia has obviously failed as a treatment in both asthma and rhinitis. 8 Holmberg et al9 have recently shown that topical lignocaine has no effect on allergen induced nasal symptoms. These and other human data on nasal conditions'01 currently give little support for the view that axon reflexes and neurogenic inflammation are major components of allergic airway diseases.
Aubier and coworkers'2 recently reported that bronchial hyperresponsiveness associated with allergic rhinitis is more effectively treated by nasal than by bronchial glucocorticoid administration. In 1984 Henriksen and Wenzel" showed that intranasal glucocorticoid treatment produced significant effects on real asthma and its hyperresponsiveness. In 1988 Reed et al were surprised to find that intranasal anti-inflammatory treatment prevented seasonal asthma. It seems unfortunate that the value of improving the health of nasal passages in asthma has received so little attention in the last few decades.
Steroids and sympathomimetics
In 1872 Theodor Weber" presented a "SchwellungTheorie" explaining obstruction in rhinitis and asthma as a vasodilatory phenomenon. Weber thought of asthma as a "bronchial urticaria" and the supportive evidence for his theory rested largely on reactions in the nose. The earliest picture indicating a profuse bronchial mucosal vasculature in asthma may have been drawn by Fraenkel'6 Figure 1 The epithelial lining and the profuse subepithelial microcirculation, two major tissue components in airway inflammation, which may be largely similar in nasal and tracheobronchial airways. A smooth muscle layer corresponding to the bronchial muscle does not exist in the nose, which instead harbours large sinus veins. The latter structures may, less conspicuously, be found also in bronchial tissue (not shown).
Thorax 1992;47:993-1000 Solis-Cohen suffered from asthma and seasonal rhinitis. He shared the notion that both asthma and rhinitis were characterised by a "vasomotor ataxia of a relaxing variety."19 He ingested dried bovine adrenals, a material that possessed vasoconstrictor properties. Not only was his own airway disease improved, but his asthmatic patients improved significantly with daily ingestion of this "adrenal substance." '9 The oral efficacy and the slowly developing clinical effect suggest that corticosteroid and not sympathomimetic actions were responsible.2 Soon after Solis-Cohen's report purified adrenaline became available. Again, the first known pharmacological action was vasoconstriction. Bullowa and Kaplan,20 who discovered the antiasthmatic property of adrenaline injections, concluded that it was vasodilatation and not bronchoconstriction that caused the airflow obstruction in asthma. This view was reversed when adrenaline induced bronchodilatation was demonstrated.8 Today still more airway actions of sympathomimetic drugs have been found.
Studies on whole animal models and isolated cells suggest that f2 agonists may inhibit mast cells, reduce vascular permeability, and attenuate allergen induced airway eosinophilia.2'22 The response of the nasal mucosa challenged with allergen and inflammatory mediators includes mast cell activation, plasma exudation, eosinophil accumulation and activation, and neural activation. Nasal studies may therefore be helpful in determining whether topical f2 agonists can inhibit these effects in vivo in human airways, and also whether these drugs may have mucosal effects that are less desirable. Bronchodilator effects clearly cannot be predicted from any nasal experiments. The lack of dilator and constrictor smooth muscle in the nasal mucosa (fig 1) , however, may also be considered an experimental advantage. In the nose airway mucosal actions of drugs and mediators can thus be examined in detail and over large dose ranges without the disturbance and the severe limitations that are imposed in the lower airways by effects on bronchial smooth muscle tone.
A continued focus on the nose has been helpful in delineating airway anti-inflammatory actions of glucocorticoid drugs. When adrenocorticotrophic hormone and cortisone became available, ear, nose, and throat and pulmonary specialists in Johns Hopkins Hospital in Baltimore were the first to examine the effects of these agents in severe asthma.22' Dramatic improvements were recorded. Furthermore, the careful inspections of the nose performed by these workers showed that the mucosal exudations and secretions and the eosinophilia disappeared.
Eosinophils, mast cells, and the epithelium Some of the reports on the pathology of asthma in the early 1900s are based on examinations of the entire respiratory tract in patients who never received disease modifying antiinflammatory treatment. Despite the importance of many of these studies (two have already been mentioned'6 17) they cannot be traced easily in currently available publications. In 1916 Felix Marchand24 reported on the presence of eosinophils, mast cells, and other cells in the nasal and bronchial mucosa of patients who had died from asthma. Eosinophils were abundant both in the epithelium and in other parts of the nasal and bronchial airways, and sometimes also in the muscle and the peribronchium. He found leucocytes attached to fibrin threads in the sputum, and even found eosinophils in samples ofasthmatic sputum that had been well preserved since 1854. Marchand plasma exudation is readily induced by "non-inflammatory" factors that merely evoke a neural response67 as well as by immune mediated mechanisms. In the human airways, however, irritant induced neural actions that increase blood flow and secretion, induce sneezing, and even cause pain do not produce any mucosal exudation of plasma.'01' Plasma exudation thus seems to be a specific inflammatory response in human airways. It is also a general response in the sense that it occurs regardless of which cellular or non-cellular mechanism drives the inflammation. Hence mucosal exudation of plasma reflects equally the inflammatory airway response in allergy and in infection. A plasma exudate not only is a measure ofthe intensity of inflammation but also contributes to the vicious circles and sequelae of airway inflammation (fig 3) . The airway mucosal surface appears to be the main destination of the plasma exudate that is produced by mucosal challenges.707' Exudative indices analysed in mucosal surface liquids may thus promptly and quantitatively reflect subepithelial inflammatory processes. 67 Such agreement between mucosal surface and subepithelium may not be valid for the cellular indices ofinflammation. As observed in both allergic rhinitis and asthma, the efficacy of glucocorticoid treatment may be assessed by monitoring exudative indices in airway discharges.707273 Effective topical glucocorticoid treatment also prevents the appearance of plasma derived mediators, such as bradykinin, on the mucosal surface.72 Work on the human nose suggests that topical glucocorticoids may not produce appreciable vasoconstriction,74 nor may they produce direct venular antipermeability effects in the airways. 75 Moreover, agents that produce significant vasoconstriction such as topical oximetazolin (an a adrenoceptor agonist) may not affect the mucosal exudation process,76 probably because the profuse subepithelial microcirculation provides the mucosa with a surplus of blood. The antiexudative effects oftopical airway glucocorticoids therefore reflectanti-inflammatory ratherthan simplevasculareffects. Corticosteroids have many actions, and the exact mechanisms that are crucial to their anti-inflammatory and antiexudative effect remain speculative.
The idea that plasma extravasation is a specific and unifying characteristic of tissue inflammation originated with the astute observations of Virchow's pupil Cohnheim.77 He also noted that the extravasation of leucocytes was a distinctly different phenomenon, though it frequently occurred in inflammation and took place across the same microvessels that exuded the plasma.
Airway inflammation is not pulmonary inflammation
The airway mucosa receives systemic arterial blood and the airway microvessels respond with plasma exudation to many inflammatory stimuli that may not affect the pulmonary circulation. On the other hand, pulmonary inflammation may be produced by distinct pulmonary microvascular-alveolar mechanisms that may not apply to the airway microcirculation and epithelium. diseases'4 (fig 3) .
The presence of plasma proteins in rhinitic and asthmatic airways cannot be considered evidence of a general hyperpermeability of the epithelial lining, though this has been a popular belief. Similarly, we may no longer say that luminal plasma proteins reflect airway epithelial damage and disruption. The denudation of the airway epithelium in asthma is now supported by data from biopsy material but artefactual changes associated with the biopsy may have played a part.89'" Nasal biopsy and functional data suggest that longstanding allergic inflammation may not be associated with epithelial damage. Indeed, the airway epithelial lining becomes tighter rather than more permeable during the birch pollen season.92 Increased epithelium tightness has thus been observed in an exudative airway disease where the mucosa has been endowed with activated eosinophils for several weeks. 30 92 Studies on the absorption ability of the airway mucosa cannot have the same specificity in the bronchi as in the nose. A careful investigation by Elwood et al,93 however, indicated that bronchial absorption may not be increased in asthma or bronchial hyperresponsiveness. Whereas these observations agree with data on the integrity of the epithelial barrier in rhinitis they are at variance with the generally adopted notion that epithelial damage and denudation are characteristics of asthma.
Mucosal hyperresponsiveness
In asthma the techniques of standardised challenge and spirometry are used to identify airway hyperresponsiveness. The precise quantitative definition ofwhat constitutes bronchial hyperresponsiveness in clinical tests94 is not matched by a precise knowledge of which factors are contributing to this phenomenon. The response of the lungs to histamine, methacholine, and other challenges thus reflects a "black box" of airway hyperresponsiveness. Furthermore, increased responsiveness may not always identify asthma or even inflammation in asthma.95 Altered responsiveness of the end organs of the mucosa may be induced by inflammatory processes in the airways, and such functional alterations in the mucosa may prove to be important characteristics of asthma and rhinitis. As the nose lacks smooth muscle, histamine and methacholine challenges provide an opportunity to examine the specific end organ reactivity of the airway mucosa. Histamine (as well as bradykinin and LTD4) can selectively assess the exudative responsiveness of the mucosal microcirculation.8' 9 Methacholine is without exudative effects67 97 and may be used to assess the secretory responsiveness of the airway mucosa. Hyperresponsiveness of the sensory nerves can be detected by nasal challenges with capsaicin or nicotine." 9' The tissue responses to these neurogenic stimuli include increases in secretion98 and blood flow (in human airways the neural stimulation does not produce plasma exudation'0 "). 
